Very recently, its HDAC inhibitor activity was also shown to be associated with a favorable clinical response in patients with breast cancer receiving entinostat and anti-hormonal therapy (ENCORE 301 phase II clinical study) [43]. Here, HDAC9 is linked to breast carcinoma.